NCT01084863View on ClinicalTrials.gov

Evaluate Safety, Efficacy and Pharmacokinetics

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

143

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2023

Conditions
Metastatic Breast Cancer
Interventions
DRUG

CT-P6

CT-P6: administered every 3 weeks

DRUG

Herceptin

Herceptin: administered every 3 weeks

DRUG

Paclitaxel

Paclitaxel: administered every 3 weeks

Trial Locations (1)

Unknown

Samsung Medical Center, Seoul

Sponsors

Lead Sponsor

Celltrion
All Listed Sponsors
lead

Celltrion

INDUSTRY

NCT01084863 - Evaluate Safety, Efficacy and Pharmacokinetics | Biotech Hunter | Biotech Hunter